mPEG-PCL for docetaxel delivery to prostate cancer

--

NOTE: mPEG-PCL (AK036) thermogelation properties vary depending on storage time and also conditions such as warming, etc. which lead to self-crystallization of the PCL chains. This material may work as a thermogel but its performance is unreliable. If the batch you have is not thermogelling dissolve in organic solvent (DCM) and dry off quickly to reset polymer chain configuration.  

--

PolySciTech (www.polyscitech.com) provides a variety of mPEG-PCL copolymers such as polyvivo AK01, AK36 and others. Recently mPEG-PCL polymers were utilized to improve delivery of docetaxel to prostate cancer. Read more: Jin, Ming-ji, Sheng-jun Piao, Tie-xiong Jin, Zhe-hu Jin, Xue-zhe Yin, and Zhong-gao Gao. "Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles." Journal of Huazhong University of Science and Technology [Medical Sciences] 34 (2014): 66-75.  http://link.springer.com/article/10.1007/s11596-014-1233-0

“Summary: This study primarily focused on the systematic assessment of both in vitro and in vivo anti-tumor effects of docetaxel-loaded polyethylene glycol (PEG)2000-polycaprolactone (PCL)2600 micelles on hormone-refractory prostate cancer (HRPC). By using solvent evaporation method, PEG-PCL was chosen to prepare doxetaxel (DTX)-loaded mPEG-PCL micelles (DTX-PMs), with the purpose of eliminating side effects of the commercial formulation (Tween 80) and prolonging the blood circulation time. The prepared DTX-PMs had an average particle size of 25.19±2.36 nm, a zeta potential of 0.64±0.15 mV, a polydispersity index of 0.56±0.03, a drug loading of (8.72±1.05)%, and an encapsulation efficiency of (98.1±8.4)%. In vitro cytotoxicity studies indicated that DTX-PMs could effectively kill LNCap-C4-2B cells and show a dose- and time-dependent efficacy. The hemolysis test showed that DTX-PMs had less hemocytolysis than the commercial product of Duopafei®. A sustained in vitro release behavior and prolonged circulation time in blood vessels were observed in the DTX-PMs. Furthermore, when compared with Duopafei®, the DTX-PMs dramatically reduced the prostate specific antigen (PSA) level and tumor growth of prostate tumor-bearing nude mice in vivo. In conclusion, the DTX-PMs can lower systemic side effects, improve anti-tumor activity with prolonged blood circulation time, and will bring an alternative to patients with HRPC.”